Summary:
- This article discusses a new biotech startup that is developing a drug based on the GLP-1 hormone, which is typically used to treat diabetes, as a potential treatment for addiction.
- The startup, called Avedro Therapeutics, believes that by targeting the GLP-1 receptor in the brain, they can reduce cravings and withdrawal symptoms associated with various addictions, including alcohol, opioids, and nicotine.
- The article explains that the GLP-1 receptor is involved in regulating food intake and reward processing in the brain, suggesting it could be a promising target for addiction treatment.